Skip to main content
Zai Lab Limited logo

Zai Lab Limited — Investor Relations & Filings

Ticker · 9688 ISIN · KYG9887T1168 LEI · 549300P2UYQ9U5LY1T58 HKEX Manufacturing
Open in API
Filings indexed 388 across all filing types
Latest filing 2024-08-06 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 9688

About Zai Lab Limited

http://www.zailaboratory.com

Zai Lab Limited is an innovative, research-based, commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing transformative therapies that address medical conditions with significant unmet needs. The company focuses its pipeline and development efforts across four core therapeutic areas: oncology, immunology, neuroscience, and infectious disease. Zai Lab employs a strategy of internal research and global partnerships to advance best-in-class and first-in-class medicines. A key commercial product is ZEJULA (niraparib), utilized as a maintenance treatment for ovarian cancer in markets including mainland China.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2024
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 31 July 2024. It details movements in authorised/registered share capital, issued shares, share options, and other share-related information. It is submitted to the Hong Kong Exchanges and Clearing Limited and includes confirmations pursuant to listing rules. The content focuses on share capital changes, share options, and confirmations related to securities issuance and compliance with listing rules. There is no financial performance data, earnings information, or management discussion. The document is a regulatory submission about share capital movements and compliance, fitting the category of a Regulatory Filing (RNS) rather than a full financial report or announcement of a report. The document length (11,519 characters) and detailed data support it being a substantive regulatory filing rather than a brief announcement or report publication notice.
2024-08-06 English
Notice of Audit Committee Action and Date of Publication of 2024 Interim Results Announcement
Report Publication Announcement Classification · 95% confidence The document is a notice announcing the date of publication of the company's 2024 interim results and the Audit Committee's planned approval of these results. It also announces a forthcoming earnings teleconference call and webcast to discuss the results. The document does not contain the actual interim financial results or substantive financial data but rather informs about the upcoming release and related events. The document length is 3700 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, according to the 'Menu vs Meal' rule, this document is an announcement about the publication of a report, not the report itself. Hence, the appropriate classification is Report Publication Announcement (RPA).
2024-07-25 English
OVERSEAS REGULATORY ANNOUNCEMENT - FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is an announcement by Zai Lab Limited regarding the filing of a Form 8-K with the U.S. Securities and Exchange Commission (SEC) about entering into a debt facility arrangement. The text includes the full Form 8-K content, including details of the debt facility, guarantees, credit agreements, and exhibits. The document is 7,733 characters long, which is substantial and contains detailed information about the material definitive agreement and financial obligations. It is not merely an announcement that a report is available elsewhere, but the actual Form 8-K report text itself. The Form 8-K is a current report filed pursuant to the Securities Exchange Act of 1934, typically used to disclose material events such as entering into significant agreements or financial obligations. This fits the category of Capital/Financing Update (CAP) because it relates to a new debt facility and financing arrangement. Therefore, the appropriate classification is CAP with high confidence.
2024-07-10 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return report concerning movements in securities, specifically focusing on share capital, issued shares, treasury shares, share options, and other share-related activities for Zai Lab Limited. It is addressed to the Hong Kong Exchanges and Clearing Limited and references compliance with the Exchange Listing Rules, including confirmations about authorization and regulatory compliance. The document includes detailed tables of share movements, share option schemes, and confirmations by a company director. It does not contain financial performance data, earnings, or management discussion, nor is it an announcement of a report publication. The content aligns with regulatory filings related to share capital and securities movements under exchange rules, which fits the category of Regulatory Filings (RNS) as a general regulatory announcement and compliance document that does not fit other specific categories.
2024-07-05 English
GRANT OF SHARE OPTIONS AND RESTRICTED SHARE UNITS
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the grant of share options and restricted share units under the 2024 Equity Incentive Plan. It details the number of options and restricted share units granted, the vesting periods, exercise prices, and the identities of the grantees, including an executive director and CEO. The document references compliance with Listing Rules and provides definitions related to the equity incentive plan. It is a regulatory announcement about equity compensation grants rather than a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis. The content fits the category of a Regulatory Filing (RNS) as it is a formal announcement required by stock exchange rules about share option grants and equity awards.
2024-07-02 English
(Revised) Next Day Disclosure Return
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued shares or treasury shares, including share buybacks and on-market sales of treasury shares. It references specific listing rules from the Hong Kong Stock Exchange (Main Board Rules and GEM Rules) and provides detailed data on share issuance and treasury shares. The document includes confirmations about compliance with listing rules and legal requirements. It is a regulatory disclosure about share capital changes rather than a financial report, earnings release, or management discussion. The content fits the description of a Share Issue/Capital Change announcement, as it details changes in issued shares and treasury shares, including share awards and share repurchases. Therefore, the appropriate classification is Share Issue/Capital Change (SHA). The document length (8643 characters) and detailed data support this classification with high confidence.
2024-07-02 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.